Literature DB >> 15351775

Mild overexpression of MeCP2 causes a progressive neurological disorder in mice.

Ann L Collins1, Jonathan M Levenson, Alexander P Vilaythong, Ronald Richman, Dawna L Armstrong, Jeffrey L Noebels, J David Sweatt, Huda Y Zoghbi.   

Abstract

Mutations in the X-linked methyl-CpG-binding protein 2 (MECP2), encoding a transcriptional repressor, cause Rett syndrome and a variety of related neurodevelopmental disorders. The vast majority of mutations associated with human disease are loss-of-function mutations, but precisely what aspect of MeCP2 function is responsible for these phenotypes remains unknown. We overexpressed wild-type human protein in transgenic mice using a large genomic clone containing the entire human MECP2 locus. Detailed neurobehavioral and electrophysiological studies in transgenic line MeCP2(Tg1), which expresses MeCP2 at approximately 2-fold wild-type levels, demonstrated onset of phenotypes around 10 weeks of age. Surprisingly, these mice displayed enhanced motor and contextual learning and enhanced synaptic plasticity in the hippocampus. After 20 weeks of age, however, these mice developed seizures, became hypoactive and approximately 30% of them died by 1 year of age. These data demonstrate that MeCP2 levels must be tightly regulated in vivo, and that even mild overexpression of this protein is detrimental. Furthermore, these results support the possibility that duplications or gain-of-function mutations in MECP2 might underlie some cases of X-linked delayed-onset neurobehavioral disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15351775     DOI: 10.1093/hmg/ddh282

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  249 in total

Review 1.  Complexities of Rett syndrome and MeCP2.

Authors:  Rodney C Samaco; Jeffrey L Neul
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

Review 2.  The contribution of GABAergic dysfunction to neurodevelopmental disorders.

Authors:  Kartik Ramamoorthi; Yingxi Lin
Journal:  Trends Mol Med       Date:  2011-04-21       Impact factor: 11.951

Review 3.  Epigenetic mechanisms in memory and synaptic function.

Authors:  Faraz A Sultan; Jeremy J Day
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

4.  MeCP2: only 100% will do.

Authors:  Hsiao-Tuan Chao; Huda Y Zoghbi
Journal:  Nat Neurosci       Date:  2012-01-26       Impact factor: 24.884

5.  MECP2 Duplication Syndrome.

Authors:  H Van Esch
Journal:  Mol Syndromol       Date:  2011-07-05

6.  Insights into the role of DNA methylation in disease through the use of mouse models.

Authors:  Melissa Conerly; William M Grady
Journal:  Dis Model Mech       Date:  2010 May-Jun       Impact factor: 5.758

Review 7.  The role of MeCP2 in CNS development and function.

Authors:  Elisa S Na; Lisa M Monteggia
Journal:  Horm Behav       Date:  2010-05-31       Impact factor: 3.587

8.  A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells.

Authors:  Maria C N Marchetto; Cassiano Carromeu; Allan Acab; Diana Yu; Gene W Yeo; Yangling Mu; Gong Chen; Fred H Gage; Alysson R Muotri
Journal:  Cell       Date:  2010-11-12       Impact factor: 41.582

Review 9.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

10.  Pharmacological read-through of R294X Mecp2 in a novel mouse model of Rett syndrome.

Authors:  Jonathan K Merritt; Bridget E Collins; Kirsty R Erickson; Hongwei Dong; Jeffrey L Neul
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.